The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

Oncogene

Volumn 23, Issue 31, 2004, Pages 5387-5393

  Berthou, Sylvie ^a   Aebersold, Daniel M ^a,b   Schmidt, Laura S ^c   Stroka, Deborah ^a,b   Heigl, Christine ^a   Streit, Bruno ^a   Stalder, Denise ^a   Gruber, Guenther ^a   Liang, Congxin ^d   Howlett, Anthony R ^d   Candinas, Daniel ^a   Greiner, Richard H ^a   Lipson, Kenneth E ^d   Zimmer, Yitzhak ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c SAIC FREDERICK INC   (United States)

^d SUGEN INC   (United States)

Author keywords

Activating mutation; Met receptor; Receptor tyrosine kinase inhibitor

Indexed keywords

MUTANT PROTEIN; PROTEIN KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SU 11274; UNCLASSIFIED DRUG; ((3Z) N (3 CHLOROPHENYL) 3 ((3,5 DIMETHYL 4 ((4 METHYLPIPERAZIN 1 YL)CARBONYL) 1H PYRROL 2 YL)METHYLENE) N METHYL 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONAMIDE); ((3Z)-N-(3-CHLOROPHENYL)-3-((3,5-DIMETHYL-4-((4-METHYLPIPERAZIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-N-METHYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE); ANTINEOPLASTIC AGENT; DNA; ENZYME INHIBITOR; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ARTICLE; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN 3T3; CELL STRUCTURE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC RESISTANCE; MOLECULAR MODEL; MOUSE; NONHUMAN; POINT MUTATION; PREDICTION; PRIORITY JOURNAL; PROTEIN VARIANT; SEQUENCE HOMOLOGY; ANIMAL; CELL CYCLE; CELL DIVISION; CELL LINE; CELL MOTION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE COURSE; DOSE RESPONSE; DRUG ANTAGONISM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; METASTASIS; MUTATION; SIGNAL TRANSDUCTION;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; CELL LINE; CELL MOVEMENT; CELL SURVIVAL; DISEASE PROGRESSION; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; INDOLES; MICE; MODELS, MOLECULAR; MUTATION; NEOPLASM METASTASIS; NIH 3T3 CELLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 3142691273     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207691     Document Type: Article

References (33)

1. Aebersold DM, Landt O, Berthou S, Gruber G, Beer KT, Greiner RH and Zimmer Y. (2003). Oncogene, 22, 8519-8523.
2. Azam M, Latek RR and Daley GQ. (2003). Cell, 112, 831-843.
3. Bardelli A, Longati P, Gramaglia D, Basilico C, Tamagnone L, Giordano S, Ballinari D, Michieli P and Comoglio PM. (1998). Proc. Natl. Acad. Sci. USA, 95, 14379-14383.
4. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB. (2000). J. Pharmacol. Exp. Ther., 295, 139-145.
5. Danilkovitch-Miagkova A and Zbar B. (2002). J. Clin. Invest., 109, 863-867.
6. De Silva CM and Reid R. (2003). Pathol. Oncol. Res., 9, 13-19.
7. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD and Joensuu H. (2002). N. Engl. J. Med., 347, 472-480.
8. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G and Comoglio PM. (2000). Oncogene, 19, 1547-1555.
9. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB. (1996). Nat. Med., 2, 561-566.
10. Giordano S, Maffe A, Williams TA, Artigiani S, Gual P, Bardelli A, Basilico C, Michieli P and Comoglio PM. (2000). FASEB J., 14, 399-406.
11. Graziani A, Gramaglia D, Cantley LC and Comoglio PM. (1991). J. Biol. Chem., 266, 22087-22090.
12. Haddad R, Lipson KE and Webb CP. (2001). Anticancer Res., 21, 4243-4252.
13. Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S and Vande Woude GF. (1998). Proc. Natl. Acad. Sci. USA, 95, 14417-14422.
14. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B and Vande Woude GF. (1997). Proc. Natl. Acad. Sci. USA, 94, 11445-11450.
15. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M and Morra E. (2002). N. Engl. J. Med., 346, 645-652.
16. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B and Vande Woude GF. (2000). Oncogene, 19, 4947-4953.
17. Longati P, Comoglio PM and Bardelli A. (2001). Curr. Drug Targets, 2, 41-55.
18. Lorenzato A, Olivero M, Patane S, Rosso E, Oliaro A, Comoglio PM and Di Renzo MF. (2002). Cancer Res., 62, 7025-7030.
19. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE and Salgia R. (2003). Cancer Res., 63, 6272-6281.
20. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT and Salgia R. (2002). Cytokine Growth Factor Rev., 13, 41-59.
21. Miller M, Ginalski K, Lesyng B, Nakaigawa N, Schmidt L and Zbar B. (2001). Proteins, 44, 32-43.
22. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR and Schlessinger J. (1997). Science, 276, 955-960.
23. Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B and Lee JY. (1999). Cancer Res., 59, 307-310.
24. Rege-Cambrin G, Scaravaglio P, Carozzi F, Giordano S, Ponzetto C, Comoglio PM and Saglio G. (1992). Cancer Genet. Cytogenet., 64, 170-173.
25. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL and Van Etten RA. (2002). Proc. Natl. Acad. Sci. USA, 99, 10700-10705.
26. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG and Salgia R. (2003). Cancer Res., 63, 5462-5469.
27. Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, Rusconi L and Cristiani C. (2003). Proc. Natl. Acad. Sci. USA, 100, 12654-12659.
28. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM and Zbar B. (1997). Nat. Genet., 16, 68-73.
29. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM and Zbar B. (1999). Oncogene, 18, 2343-2350.
30. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM and Sawyers CL. (2002). Blood, 99, 1928-1937.
31. To CT and Tsao MS. (1998). Oncol. Rep., 5, 1013-1024.
32. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S and Nielsen OS. (2001). Lancet, 358, 1421-1423.
33. Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, Harris D, Sun L, Rice A, Vasile S, Blake RA, Howlett AR, Patel N, McMahon G and Lipson KE. (2003). Mol. Cancer Ther., 2, 1085-1092.